The history of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial release generated significant profits, the end of its intellectual property protection opened the floodgates to off-brand versions, dramatically diminishing sales. This creates a unique challenge for firms depending on related blockbuster

The legacy of Viagra, and its creator copyright, presents a intriguing case study for investors. Initially a blockbuster drug, generating billions in revenue , its exclusivity period created a flood of generic competition , significantly eroding its market share . While specific pharmaceutical companies may seek to capitalize on male sexual dysfunc